Halozyme Therapeutics, Inc. (FRA:RV7)

Halozyme Therapeutics Statistics

Total Valuation

FRA:RV7 has a market cap or net worth of EUR 6.89 billion. The enterprise value is 7.61 billion.

Market Cap	6.89B
Enterprise Value	7.61B

Important Dates

The next estimated earnings date is Wednesday, February 18, 2026.

Earnings Date	Feb 18, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	117.60M
Shares Outstanding	n/a
Shares Change (YoY)	-3.31%
Shares Change (QoQ)	-1.47%
Owned by Insiders (%)	1.11%
Owned by Institutions (%)	103.84%
Float	116.19M

Valuation Ratios

The trailing PE ratio is 13.57 and the forward PE ratio is 8.52.

PE Ratio	13.57
Forward PE	8.52
PS Ratio	6.50
PB Ratio	16.04
P/TBV Ratio	n/a
P/FCF Ratio	13.42
P/OCF Ratio	13.23
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 10.76, with an EV/FCF ratio of 14.82.

EV / Earnings	14.99
EV / Sales	7.12
EV / EBITDA	10.76
EV / EBIT	12.00
EV / FCF	14.82

Financial Position

The company has a current ratio of 1.59, with a Debt / Equity ratio of 3.05.

Current Ratio	1.59
Quick Ratio	1.25
Debt / Equity	3.05
Debt / EBITDA	1.87
Debt / FCF	2.55
Interest Coverage	41.53

Financial Efficiency

Return on equity (ROE) is 124.50% and return on invested capital (ROIC) is 22.87%.

Return on Equity (ROE)	124.50%
Return on Assets (ROA)	21.24%
Return on Invested Capital (ROIC)	22.87%
Return on Capital Employed (ROCE)	53.28%
Revenue Per Employee	3.03M
Profits Per Employee	1.45M
Employee Count	350
Asset Turnover	0.57
Inventory Turnover	1.65

Taxes

In the past 12 months, FRA:RV7 has paid 128.23 million in taxes.

Income Tax	128.23M
Effective Tax Rate	20.17%

Stock Price Statistics

The stock price has increased by +34.73% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+34.73%
50-Day Moving Average	59.59
200-Day Moving Average	54.97
Relative Strength Index (RSI)	52.95
Average Volume (20 Days)	66

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	5.67

Income Statement

In the last 12 months, FRA:RV7 had revenue of EUR 1.06 billion and earned 507.54 million in profits. Earnings per share was 4.04.

Revenue	1.06B
Gross Profit	835.90M
Operating Income	628.48M
Pretax Income	635.76M
Net Income	507.54M
EBITDA	693.16M
EBIT	628.48M
Earnings Per Share (EPS)	4.04

Balance Sheet

The company has 598.28 million in cash and 1.31 billion in debt, giving a net cash position of -713.29 million.

Cash & Cash Equivalents	598.28M
Total Debt	1.31B
Net Cash	-713.29M
Net Cash Per Share	n/a
Equity (Book Value)	429.49M
Book Value Per Share	3.65
Working Capital	418.92M

Cash Flow

In the last 12 months, operating cash flow was 520.75 million and capital expenditures -7.33 million, giving a free cash flow of 513.43 million.

Operating Cash Flow	520.75M
Capital Expenditures	-7.33M
Free Cash Flow	513.43M
FCF Per Share	n/a

Margins

Gross margin is 78.91%, with operating and profit margins of 59.33% and 47.91%.

Gross Margin	78.91%
Operating Margin	59.33%
Pretax Margin	60.02%
Profit Margin	47.91%
EBITDA Margin	65.44%
EBIT Margin	59.33%
FCF Margin	48.47%

Dividends & Yields

FRA:RV7 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	3.31%
Shareholder Yield	3.31%
Earnings Yield	7.37%
FCF Yield	7.45%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:RV7 has an Altman Z-Score of 4.74 and a Piotroski F-Score of 7.

Altman Z-Score	4.74
Piotroski F-Score	7